NKTR

Nektar Therapeutics reported a wider-than-expected loss per share, but the stock still reacted positively, rising 1.6%. Investors may be encouraged by management's comments on their pipeline and future prospects, despite the lack of revenue details and guidance. The slight stock increase suggests that the market is willing to overlook current losses in favor of potential future growth.